This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CYP2D6 / Cytochrome P450 2D6 · IHC design guide
Design Immunohistochemistry for CYP2D6
Plan CYP2D6 chromogenic IHC around high cytoplasmic staining in hepatocytes (HPA tissue IHC). This guide covers paraffin-section staining with an IHC-validated antibody (datasheet A00498-1) and liver background controls (standard IHC practice).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CYP2D6 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Hepatocyte cytoplasm (HPA tissue IHC); ER membrane (UniProt) | |
| Staining pattern | High cytoplasmic staining in hepatocytes (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A00498-1) | |
| Positive control | Liver | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Endogenous liver peroxidase can add DAB background (standard IHC practice) | |
| Regulation | Expression regulation unannotated (UniProt) | |
| Isoform / epitope | 2 isoforms; check epitope coverage (UniProt) |
Section 1
Recommended CYP2D6 IHC & IF Protocols
The catalog antibody protocol is accompanied by four published CYP2D6 IHC protocols: three for paraffin sections and one for frozen mouse brain sections.
| Sample | Paraffin-embedded rat intestine tissues; fixative not specified (datasheet A00498-1) |
| Fixation | Image fixative and duration unreported (datasheet A00498-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A00498-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00498-1) |
| Primary antibody | Rabbit anti-CYP2D6, 0.5-1μg/ml (datasheet A00498-1) |
| Primary incubation | Overnight at 4 °C (datasheet A00498-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00498-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CYP2D6-positive staining in hepatocytes of liver (HPA tissue IHC: High). HPA tissue profile: High cytoplasmic expression in liver. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with heat-mediated citrate retrieval at pH 6 (datasheet: A00498-1); published paraffin protocols also used citrate retrieval (PMC6771233; PMC9759570).
Section 2
What Is the Expected CYP2D6 Staining Pattern?
CYP2D6 is associated with the endoplasmic reticulum and microsomal membranes, although UniProt annotates no transmembrane segment (UniProt P10635). In paraffin-section IHC, expect strong cytoplasmic staining in hepatocytes (HPA tissue IHC: High in hepatocytes). HPA rates the tissue staining Enhanced but reports medium consistency between antibody staining and RNA expression (HPA tissue IHC).
| Strong chromogenic signal lies within hepatocyte cytoplasm, with identifiable cell outlines. | This matches the reported liver pattern (HPA tissue IHC: High cytoplasmic expression in hepatocytes). Score the cellular signal against adjacent background and the negative control section (standard IHC practice). |
| Signal is predominantly nuclear, with little hepatocyte cytoplasmic staining. | An isolated nuclear pattern does not match the reported tissue pattern (HPA tissue IHC: hepatocyte cytoplasm). Check the counterstain and compare with a no-primary control before assigning the chromogen to CYP2D6 (standard IHC practice). |
| Strong staining appears in adipocytes or adrenal glandular cells. | HPA reports CYP2D6 as not detected in those sampled cell populations (HPA tissue IHC). Investigate nonspecific antibody binding or endogenous detection activity; a single unexpected positive section does not establish a new CYP2D6 tissue pattern (standard IHC practice). |
| Diffuse color covers tissue and spaces between cells, obscuring cell boundaries. | This cannot be scored as the reported hepatocyte cytoplasmic pattern (HPA tissue IHC). A no-primary control can help distinguish detection-system background from antibody-associated staining (standard IHC practice). |
| Hepatocytes show no discernible signal in a liver section. | That conflicts with the reported high liver signal (HPA tissue IHC: High in hepatocytes). First verify that the section, detection reagents, and positive control worked; a negative slide alone cannot establish absent CYP2D6 expression (standard IHC practice). |
💡Expected CYP2D6 appearanceCall positive when hepatocytes show high, cell-associated cytoplasmic chromogenic staining (HPA tissue IHC); isolated nuclear color or staining confined to a reported negative cell population warrants investigation (HPA tissue IHC; standard IHC practice).
| Tissue and cell choice | Liver hepatocytes provide the reported high-signal reference; small-intestinal enterocytes are reported low, while sampled adipocytes and adrenal glandular cells are not detected (HPA tissue IHC). Compare the named cell populations, not whole-organ color. |
| Compartment and topology | UniProt places CYP2D6 at endoplasmic reticulum and microsomal membranes and annotates no transmembrane segment (UniProt P10635). The tissue-IHC readout is cytoplasmic (HPA tissue IHC); chromogenic IHC need not resolve individual organelles. |
| Strength of the tissue reference | The tissue profile is rated Enhanced, and antibody HPA045223 has Enhanced IHC validation (HPA tissue IHC; HPA antibodies). HPA also reports medium staining-to-RNA consistency, so interpret an unexpected sample with controls rather than treating the reference as absolute (HPA tissue IHC). |
| IF/ICC Q: Should its Golgi pattern define the paraffin-IHC positive call? | A: HPA calls Golgi the approved main location in ICC-IF, but reports hepatocyte cytoplasm in tissue IHC (HPA subcellular ICC-IF; HPA tissue IHC). Use the assay-specific observation; HPA045223 has Uncertain ICC validation (HPA antibodies). |
| Isoform scope | UniProt lists 2 CYP2D6 isoforms (UniProt P10635). The supplied antibody record gives no epitope or isoform-specific staining result (HPA antibodies), so a section cannot be scored as one isoform from these sources alone. |
| Situation | Likely cause | Next action |
|---|---|---|
| Liver positive control is blank. | The expected hepatocyte signal is absent (HPA tissue IHC: High in hepatocytes); the slide alone does not identify which IHC step failed. | Check section identity, reagent coverage, detection and chromogen performance, then review antigen-retrieval conditions using the antibody's validated IHC-P instructions (standard IHC practice). |
| Adipocytes or adrenal glandular cells stain strongly. | These populations are reported not detected (HPA tissue IHC); nonspecific binding or endogenous detection activity is possible (standard IHC practice). | Compare a matched no-primary control and review blocking and detection controls before scoring those cells as positive (standard IHC practice). |
| Signal looks nuclear rather than cytoplasmic. | A nuclear-dominant pattern conflicts with the reported hepatocyte cytoplasmic staining (HPA tissue IHC). Counterstain overlap may also confuse the visual readout (standard IHC practice). | Inspect chromogen and counterstain separately where possible, and compare liver with its no-primary control (standard IHC practice). |
| Diffuse color prevents cell-by-cell scoring. | Background obscures the reported cell-associated pattern (HPA tissue IHC: hepatocyte cytoplasm); its source cannot be assigned from the test section alone. | Inspect no-primary and detection controls, then review blocking, washes and chromogen development (standard IHC practice). |
| Only a faint signal appears in liver. | The result is weaker than the reported high hepatocyte staining (HPA tissue IHC); the supplied sources do not establish a CYP2D6-specific fixation effect. | Confirm the tissue and antibody identity, compare a validated positive control, and use the antibody's documented IHC-P conditions when reviewing the run (standard IHC practice). |
| The entire section appears positive. | Uniform color cannot distinguish high hepatocyte staining from the reported not-detected populations (HPA tissue IHC). Detection-system background is possible (standard IHC practice). | Examine a no-primary section and reported negative cell populations, then score only interpretable cellular staining (HPA tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing CYP2D6 staining
A00498-1 · IHCIHC analysis of Cytochrome P450 2D6 using anti-Cytochrome P450 2D6 antibody (A00498-1). Cytochrome P450 2D6 was detected in paraffin-embedde
A00498-1 · IHCIHC analysis of Cytochrome P450 2D6 using anti-Cytochrome P450 2D6 antibody (A00498-1). Cytochrome P450 2D6 was detected in paraffin-embedde
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/cerebral+cortex#imid_21037323
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/colon#imid_21039625
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/liver#imid_21039618
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/kidney#imid_21039627
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA045223; green = CYP2D6, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA045223; green = CYP2D6, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CYP2D6 IHC & IF
🧪Run liver first and score hepatocytes for strong staining (HPA: High in hepatocytes). Use adipose tissue adipocytes as a biological negative (HPA: Not detected in adipocytes); on the liver slide, compare hepatocytes with nonhepatocyte areas as an internal background check, without assuming every nonhepatocyte is negative (HPA: High in hepatocytes).
Positive control tissue: Liver (Hepatocytes, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CYP2D6 in A-431, U-251MG, U2OS, with annotated localisation: Golgi apparatus (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a concentration-matched rabbit IgG isotype control matched to the primary antibody’s clonality; a CYP2D6 knockout specimen is the preferred target-specific negative (caption: rabbit primary antibody; standard IHC practice). For liver, quench endogenous peroxidase and check endogenous biotin background when using the caption’s streptavidin–biotin/DAB detection (caption: SABC with DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A00498-1 tissue-IHC caption does not report a fixative (caption: fixative not stated). The caption uses heat retrieval in citrate buffer at pH 6 for 20 minutes on a paraffin section, but does not establish that retrieval is required for liver (caption: rat intestine tissue-IHC). Frozen sections or IF cannot be judged easier from the supplied evidence; for liver chromogenic staining, endogenous peroxidase and biotin may contribute background with the reported detection system (caption: SABC with DAB; standard IHC practice).
HPA tissue IHC evidence for CYP2D6
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Liver | Hepatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CYP2D6 IHC Tips
Troubleshoot CYP2D6 staining in paraffin sections by checking retrieval, controls, compartmental pattern, and scoring before interpreting signal.
What retrieval conditions should I start with for CYP2D6 paraffin IHC?
Start with heat-mediated retrieval in citrate buffer at pH 6 (datasheet A00498-1). The selected antibody’s rat-intestine paraffin-section image used 20 minutes of retrieval under those conditions, followed by overnight primary incubation at 4°C (caption A00498-1). Keep section thickness, heating method, and cooling time consistent while comparing a liver positive-control section with a no-primary control; liver hepatocytes show high staining in HPA tissue IHC (HPA tissue IHC; standard IHC practice). If staining remains weak, vary heating time on adjacent sections before trying another buffer, and judge any gain against tissue damage and background (standard IHC practice).
Could fixation explain weak CYP2D6 staining in my paraffin sections?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state a fixative, and the supplied record provides no fixation study (caption A00498-1; UniProt P10635 record). Record the fixative, fixation duration, specimen size, and processing schedule for each block so weak staining can be compared with a similarly processed positive control (standard IHC practice). Avoid treating a liver-versus-intestine staining difference as evidence of fixation sensitivity, because HPA reports high hepatocyte staining and low enterocyte staining (HPA tissue IHC). If replicate sections disagree, compare retrieval and antibody incubation under identical detection conditions before assigning the difference to fixation (standard IHC practice).
Which cellular pattern should count as plausible CYP2D6 staining?
Expect a predominantly cytoplasmic pattern in hepatocytes on tissue sections, consistent with HPA’s high liver cytoplasmic expression (HPA tissue IHC). UniProt places CYP2D6 at the endoplasmic reticulum and microsome membranes, while HPA subcellular imaging reports a mainly Golgi location; these sources support checking an intracellular cytoplasmic pattern but do not establish identical organelle resolution in chromogenic sections (UniProt P10635 subcellular; HPA subcellular). Compare distribution with morphology and a no-primary section before scoring dense puncta or diffuse stain (standard IHC practice). Predominantly nuclear, extracellular, or uniform luminal DAB should prompt inspection for counterstain overlap, precipitate, or endogenous enzyme activity (standard IHC practice).
How should unknown epitope coverage affect CYP2D6 IHC interpretation?
The supplied record lists 2 CYP2D6 isoforms, but the selected antibody caption does not map its epitope or establish isoform-specific recognition (UniProt P10635 isoforms; caption A00498-1). Do not label a positive section as isoform 1 or 2 without separate epitope and validation evidence (UniProt P10635 isoforms; standard IHC practice). UniProt annotates a 497-amino-acid chain and no glycosylation sites or modified residues; those annotations do not predict which fixed-section epitope this antibody detects (UniProt P10635 processing and PTMs). If samples yield discordant staining, compare a second independently validated epitope and matched controls before attributing the difference to splicing (standard IHC practice).
How can I use IF to investigate an ambiguous CYP2D6 IHC pattern?
Use IF as a separate validation experiment and multiplex CYP2D6 with a hepatocyte marker when investigating liver, where HPA reports high hepatocyte expression (HPA tissue IHC; standard IF practice). Select fluorophores after measuring unstained-section autofluorescence, and include single-color and no-primary controls to check bleed-through and background (standard IF practice). CYP2D6 is associated with endoplasmic reticulum and microsome membranes, but its antibody epitope and membrane-facing side are unspecified (UniProt P10635 subcellular; caption A00498-1). Compare gentle and stronger permeabilisation on matched specimens to establish epitope access while monitoring morphology, and do not transfer the paraffin IHC retrieval conditions directly to IF (standard IF practice; caption A00498-1).
What should I change when CYP2D6 DAB staining is widespread?
Check a no-primary section first to identify signal from detection reagents or endogenous peroxidase, then apply a peroxidase block before DAB development as part of the general chromogenic workflow (standard IHC practice). The selected rat-intestine example used 10% goat-serum block, 1 µg/mL primary antibody overnight at 4°C, and a biotin-based secondary system (caption A00498-1). Titrate primary concentration and shorten chromogen development on matched sections if nonspecific color persists, keeping retrieval fixed during that comparison (standard IHC practice). For the biotin-based system, assess reagent-only background separately, and compare cellular staining with the expected hepatocyte-rich liver pattern (caption A00498-1; HPA tissue IHC; standard IHC practice).
How should I quantify CYP2D6 staining across liver sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the analysis compartment as viable hepatocytes and score the percentage of positive cells alongside staining intensity, or combine them in an H-score, using one threshold across the comparison (HPA tissue IHC; standard IHC practice). Record the number of evaluable hepatocytes and normalize positive-cell counts to that denominator; for spatial analyses, report stained area or positive-cell density per mm² of viable tissue (standard IHC practice). Keep section thickness, retrieval, antibody incubation, DAB development, imaging, and counterstain consistent across slides (standard IHC practice). Include a no-primary control and report any excluded folds, edges, or necrotic regions so staining differences remain interpretable (standard IHC practice).
When is CYP2D6 staining more likely artefact than true signal?
A convincing result shows intracellular staining in morphologically intact hepatocytes, which HPA identifies as strongly positive in liver tissue IHC (HPA tissue IHC). Treat predominantly nuclear or extracellular color, staining concentrated only at section edges, and deposits over necrotic areas as suspect until controls and morphology support them (standard IHC practice). Run a no-primary control to reveal endogenous enzyme or detection-system color, especially when using DAB and the caption’s biotin-based detection scheme (caption A00498-1; standard IHC practice). Low enterocyte staining is reported by HPA, so interpret a strong intestinal signal in the selected rat example with species, assay, and matched-control context rather than equating the two observations (HPA tissue IHC; caption A00498-1).
Boster reagents
Best CYP2D6 / Cytochrome P450 2D6 IHC Antibodies
A00498-1 has IHC images from paraffin-embedded rat and mouse intestine, mouse liver, and human liver cancer (A00498-1 IHC captions); M00498 lists human IHC and IF/ICC applications without supplied images (M00498 catalog).
Real IHC data
Anti-Cytochrome P450 2D6/CYP2D6 Antibody ®
Cat # A00498-1
A00498-1 will render with a rat-intestine IHC figure; its other captions document mouse intestine, mouse liver, and human liver cancer in paraffin sections (A00498-1 IHC captions). M00498 will render as a human-reactive antibody listed for IHC and IF/ICC, with no IHC or IF image supplied (M00498 applications/reactivity; image lists).
Which to pick: For tissue IHC, choose A00498-1: its own rat-intestine caption documents paraffin sections, citrate retrieval at pH 6, and 1 μg/ml primary antibody; the fixative is unreported (A00498-1 IHC caption). For IF/ICC, M00498 is the listed rabbit monoclonal option, though no IF image is supplied (M00498 applications/host/clone; IF image list). For cross-species IHC, A00498-1 lists human, mouse, and rat reactivity and has paraffin-section captions for all three; M00498 lists human reactivity only (A00498-1 reactivity/IHC captions; M00498 reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P10635 (CP2D6_HUMAN, Cytochrome P450 2D6).
- Human Protein Atlas. CYP2D6 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. CYP2D6 subcellular location (ICC-IF): Mainly localized to the Golgi apparatus..
- Human Protein Atlas. CYP2D6 antibody validation summary (1 antibodies).
- Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nature cell biology 2015 — PMC4612439.
- Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening. Theranostics 2019 — PMC6771233.
- Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism. Scientific reports 2022 — PMC9759570.
- Potential role of CYP2D6 in the central nervous system. Xenobiotica; the fate of foreign compounds in biological systems 2013 — PMC3750078.
- PubMed PMID:3410476 — UniProt-cited evidence.
- PubMed PMID:3123997 — UniProt-cited evidence.
- PubMed PMID:2574001 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CYP2D6 (Cytochrome P450 2D6). Expected localisation Hepatocyte cytoplasm (HPA tissue IHC); ER membrane (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A00498-1). Validated IHC antibody: A00498-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Liver (Hepatocytes); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded rat intestine tissues; fixative not specified (datasheet A00498-1); 2. Fixation: Image fixative and duration unreported (datasheet A00498-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A00498-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00498-1); 8. Primary antibody: Rabbit anti-CYP2D6, 0.5-1μg/ml (datasheet A00498-1); 9. Primary incubation: Overnight at 4 °C (datasheet A00498-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Endogenous liver peroxidase can add DAB background (standard IHC practice); Isoform / epitope: 2 isoforms; check epitope coverage (UniProt); Regulation: Expression regulation unannotated (UniProt). Evidence: UniProt P10635, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the Golgi apparatus., Datasheet A00498-1, PMC4612439, PMC6771233. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CYP2D6/immunohistochemistry-ihc-guide.